MINI FUTURE SHORT - NOVO-NORDISK B | Market Closed - Deutsche Boerse AG 10:21:03 2024-06-21 EDT | ||
| 1.13 EUR | -0.88% |
|
| Current month | -41.45% | ||
| 1 month | -42.93% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-21 | 1.13 | -0.88% |
| 24-06-20 | 1.14 | -8.80% |
| 24-06-19 | 1.25 | 0.00% |
| 24-06-18 | 1.25 | +6.84% |
| 24-06-17 | 1.17 | +7.34% |
Delayed Quote Deutsche Boerse AG
Last update June 21, 2024 at 10:21 am
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| WKN | PN9V7M |
| ISIN | DE000PN9V7M1 |
| Date issued | 2023-10-17 |
| Strike | 1,072 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 4.76 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.75 € |
|---|---|
| Lowest since issue | 1.06 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
987.9
DKK
Average target price
934.3
DKK
Spread / Average Target
-5.43%
- Stock Market
- Certificates
- Certificat
